Logo

Novartis Reports US FDA’s Approval of Fabhalta (iptacopan) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Share this
Novartis

Novartis Reports US FDA’s Approval of Fabhalta (iptacopan) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Shots:

  • The approval was based on the P-III (APPLY-PNH) & (APPOINT-PNH) trials evaluating Fabhalta (200mg, oral, BID) vs anti-C5 therapies & Fabhalta alone in PNH patients with residual anemia & those naïve to complement inhibitor (incl. anti-C5 therapies) respectively for 24wks.
  • The results depicted that of the patients with a sustained increase of Hb levels ≥2g/dL from baseline in the absence of transfusions, responses were seen in 82.3% vs 0% of patients in (APPLY-PNH) & 77.5% of patients in (APPOINT-PNH) study
  • Furthermore, of the patients with a sustained increase of Hb levels ≥12g/dL in the absence of transfusions, responses were seen in 67.7% vs 0% of patients with a transfusion avoidance rate of 95.2% vs 45.7% in the (APPLY-PNH) study

Ref: Novartis Image: Novartis

Related News:- Novartis Reports Pre-Specified Interim Analysis Results from the P-III Study (APPLAUSE-IgAN) for Iptacopan to Treat IgA Nephropathy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions